TopFunds

Charles River Laboratories

NYSE: CRL

Stock price

297.64 USD

(+0%) TODAY

Life Sciences Tools & ServicesMedical - Diagnostics & Research

Financial Performance

Share

5Y price score: (44)

Help

The price score is a basic measure of the stock's performance against the S&P 500 Index over a five-year period.

A score of 100 indicates that the stock did as well as the S&P 500 Index.

A score below 100 means the stock underperformed the index, while a score above 100 means it outperformed the S&P 500.

10Y return: 261.6%

DATE RANGE:

US$ Per
Share

    Time scale:

    By default your notes are visible only to you.

    144.2

    52-week range

    300.5

    297.64

    Your model inputs

    Required return / cost of capital
    %
    FCFF terminal growth rate
    %

    Your fair value & Margin of safety

    To calculate fair value based on cost of capital and terminal growth assumptions above, please select free cash flow forecast.

    Forecast:

    Valuation

    Free Cash Flow Yield

    Help
    FCF Yield TTM = Trailing Twelve Months free cash flow per share / current market price per shareLearn more

    2.5 %

    Dividend Yield TTM

    -

    Market cap $

    $ 14,337

    Price / Earnings TTM

    Help
    P/E TTM = current market price per share / Trailing Twelve Months diluted earnings per shareLearn more

    (61.4)

    Price / Book TTM

    5.1

    PEG TTM

    Help
    Price/Earnings-to-Growth ratio = P/E TTM divided by most recent annual diluted earnings per share growth rateLearn more

    0.6

    Earnings growth and return

    LTM

    5YR

    10YR

    Total return (price & dividends)

    81.4 %

    (31.2) %

    261.6 %

    Free cash flow per share growth

    (10.7) %

    39.3 %

    123.3 %

    Earnings per share growth

    (102.8) %

    (140.4) %

    (193) %

    Founded: 1,947

    Employees: 18,700

    Business Summary:Charles River Laboratories International, Inc. operates as a contract research organization (CRO), providing essential preclinical services to the pharmaceutical and biotechnology industries. Its core business revolves around assisting clients with drug discovery, non-clinical development, and thorough safety testing, with its services extending globally across the United States, Europe, Canada, and the Asia Pacific region. The company organizes its diverse offerings into three principal segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. 1. Research Models and Services (RMS): This division is a key supplier of high-quality rodent research models, including specially bred strains of rats and mice for experimental purposes. It also offers a comprehensive array of support services to help clients effectively utilize these models in their research and for the screening of potential non-clinical drug candidates. These include providing genetically engineered models, insourcing solutions for facility management, and diagnostic services for research animals. 2. Discovery and Safety Assessment (DSA): The DSA segment plays a crucial role in advancing early-stage drug pipelines. It delivers early-phase and in vivo discovery services focused on identifying and validating new therapeutic targets, chemical compounds, and antibodies. The ultimate goal is to prepare promising non-clinical drug and therapeutic candidates for subsequent safety evaluations. Additionally, this segment provides an extensive range of safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism studies, and pharmacokinetics. 3. Manufacturing Solutions: This segment addresses critical quality control requirements by offering in vitro methods for both routine and rapid testing of the quality of sterile and non-sterile pharmaceuticals, as well as consumer products. It also serves as a vital provider of specialized biologics testing, which is often outsourced by pharmaceutical and biotechnology companies. Furthermore, the segment supplies avian vaccine services, including specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products, all essential for vaccine production. Beyond these specialized segments, Charles River also manages contract vivarium operations, providing crucial animal housing and care facilities for its biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

    Fair Value Reference Estimate

    Latest Earnings Call Takeaways

    2026 Q2 (Aug 5, 2026)

    1) Strategic Initiatives & Leadership Focus - Charles River Laboratories (CRL) is executing its "pathway to purpose" strategy, aimed at modernizing the company and enhancing its scientific portfolio. - The company reported a strong demand environment in the biopharmaceutical sector, particularly in the Discovery Services and Assessment (DSA) segment, with a net book-to-bill ratio of nearly 1.2x, the highest in four years. - CEO Birgit Girshick emphasized the importance of deepening client relationships, highlighted by a collaboration with Eli Lilly to support AI-driven drug discovery.

    2) Financial Performance & Segment Results - CRL's Q2 2026 revenue grew 0.1% organically, surpassing expectations of a low single-digit decline. - Non-GAAP earnings per share reached $3.02, a 47% sequential increase, exceeding prior guidance. - Operating margin improved by 420 basis points sequentially to 20.5%, driven by divestitures and reduced margin pressures. - Segment performance included: - DSA: Revenue of $607 million, with organic growth of 0.2%. - RMS: Revenue declined 1.4% organically, impacted by lower demand from North American academic and government clients. - Manufacturing: Revenue increased 1.3% organically, with expectations for mid- to high single-digit growth in the second half.

    3) Challenges & Headwinds - The RMS segment continues to face challenges, particularly from constrained spending by academic and government clients due to flat NIH budgets. - Despite a positive outlook for DSA, the company anticipates a low to mid-single-digit organic revenue decline in RMS for the year. - The impact of a higher non-GAAP tax rate, projected to be a $0.20 headwind to earnings per share, is also a concern.

    4) Operational & Product Plans - CRL is investing in lab expansions and modernization initiatives, including AI technologies to enhance operational efficiency and client service. - The company is expanding bioanalytical laboratory capacity in Scotland to support growing demand in lab sciences. - Future growth is expected to be supported by a strong pipeline of DSA bookings and improved biopharmaceutical demand trends.

    5) Guidance & Outlook - CRL raised its full-year guidance, now expecting reported revenue to decline by 2.5% to 3.5% due to divestitures, while organic revenue growth is projected to be flat to 1%. - For Q3 2026, the company anticipates a reported revenue decline of 4% to 6%, with organic growth of 1% to 3%. - The outlook for DSA revenue growth has been adjusted to low single-digit growth for the year, reflecting improved demand.

    Bottom line: CRL's strategic focus on modernization and client-centric initiatives, combined with a recovering biopharmaceutical demand environment, positions the company for improved financial performance and shareholder value in the coming quarters. However, challenges in the RMS segment and a higher tax rate present headwinds that investors should monitor closely.

    Annual Reports, Presentations And IR Contacts

    Go to the website
    Annual report links (10K)
    2025202420232022202120202019201820172016

    Charles River Laboratories — Financial Overview, Stock Price, Market Cap

    Charles River Laboratories is a company. Founded in 1947. As of August 26, 2026, the company's market capitalization is $14336634228 with a current stock price of $297.64.